Mineralys Therapeutics sees cash runway through 1Q26

Cash, cash equivalents and investments were $198.2 million as of December 31, 2024, compared to $239.0 million as of December 31, 2023. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations, through the first quarter of 2026.